Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Consequences of Gastrointestinal Surgery
NCT02836353Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jan 2017
- Primary completion
- Mar 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of somatostatin and rifaximin in dumping syndrome, sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Severity of hypoglycaemia during glucose tolerance test as measured by plasma glucose levels. Started Jan 2017; status: terminated.
02
Drugs
somatostatinrifaximin
03
Conditions
dumping syndrome
Beyond the preview
Go deeper on NCT02836353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836353.